Marine Anti-inflammatory Agents 

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 683

Special Issue Editor


E-Mail Website
Guest Editor
Organic Chemistry Unit, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, University Complutense of Madrid, Plza. Ramón y Cajal s/n, 28040 Madrid, Spain
Interests: phytomedicine; phytochemistry; natural products; drug discovery; organic and medicinal chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to inform you that I am organising a Special Issue titled “Marine Anti-inflammatory Agents 2024” in /Marine Drugs/ (ISSN: 1660-3397, https://www.mdpi.com/journal/marinedrugs). Given your distinguished expertise in this area, I warmly invite you to submit articles, short communications, or letters to this Special Issue.

Below is a brief introduction to the focus we are seeking for this Special Issue:

Inflammation, while a crucial biological response for body defence, can become dysregulated and lead to various chronic diseases. Effectively addressing inflammation is essential for improving the quality of life and preventing health complications. Marine-derived anti-inflammatory compounds are particularly valuable due to their diverse and unique chemical composition, offering new therapeutic perspectives.

Marine anti-inflammatory agents are emerging as innovative sources of new treatments. For instance, sulphated polysaccharides have shown significant effects in reducing inflammation and pain, opening new therapeutic possibilities by modulating inflammatory pathways involved in cytokine production and leukocyte migration. Likewise, cyclic peptides can effectively inhibit mast cell degranulation and the generation of inflammatory cells, showing tremendous potential in treating allergic and inflammatory diseases by modulating the release of mediators such as histamine and cytokines. Furthermore, compounds like diterpenoids and sesquiterpenoids have demonstrated significant anti-inflammatory properties by targeting enzymes involved in inflammatory processes, such as cyclooxygenases and lipoxygenases. Amino acids, such as mycosporines, have shown anti-inflammatory activity in human keratinocytes, suggesting promising applications in dermatological products by modulating inflammation induced by UV radiation and oxidative stress.

Moreover, marine lipid bioactives, such as omega-3 fatty acids, have shown significant anti-inflammatory effects by influencing the synthesis of inflammatory mediators and modulating immune responses. These compounds offer additional benefits due to their ability to integrate into cell membranes and alter inflammatory signalling cascades.

Finally, patented marine extracts like Lyprinol have demonstrated efficacy in reducing inflammation and osteoarthritis symptoms in clinical trials by targeting multiple pathways, including prostaglandin synthesis and leukotriene production. All these advancements have been made possible through advanced screening techniques that have identified new marine compounds with anti-inflammatory properties, opening new avenues for the development of innovative therapies. The application of OMIC technologies, such as lipidomics, proteomics, genomics, and metabolomics, along with structural analysis and the elucidation of structure–activity relationships, has provided a deeper understanding of how these marine compounds interact with biological systems and how they can be optimised for therapeutic applications

This field represents unexplored potential and a rich source of opportunities for researchers interested in discovering and developing new therapies based on marine natural products. We invite you to contribute your research and discoveries in this exciting and promising area of science.

Dr. Luis Apaza Ticona
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anti-inflammatory
  • marine compounds
  • sulphated polysaccharides
  • lipid bioactives
  • OMIC technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 4588 KiB  
Article
The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4/NF-κB Signaling Pathway
by Jing Liu, Xin Zeng, Yu-Quan Lin, Yu-Sheng Peng, Lan Liu, Sen-Hua Chen and Yan-Hua Du
Mar. Drugs 2025, 23(4), 145; https://doi.org/10.3390/md23040145 - 28 Mar 2025
Viewed by 364
Abstract
Isaridin E, a cyclodepsipeptide derived from the marine fungus Beauveria felina (SYSU-MS7908), has been demonstrated to possess multiple biological properties. In this study, we employed both lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) and a LPS-induced murine endotoxemia model to investigate its [...] Read more.
Isaridin E, a cyclodepsipeptide derived from the marine fungus Beauveria felina (SYSU-MS7908), has been demonstrated to possess multiple biological properties. In this study, we employed both lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) and a LPS-induced murine endotoxemia model to investigate its anti-inflammatory effects. Our results revealed that isaridin E suppressed the expression of pro-inflammatory cytokines and adhesion molecules in a concentration dependent manner, while also reducing monocyte adhesion to endothelial cells. Furthermore, this compound attenuated vascular hyperpermeability and inflammatory cell infiltration in the lungs, as well as preserving the integrity of the aortic and pulmonary tissues. At the molecular level, isaridin E was found to downregulate TLR4 expression, increase IκBα levels, and inhibit the LPS-induced phosphorylation and nuclear translocation of NF-κB p65. In conclusion, our findings indicate that isaridin E exerts robust anti-inflammatory effects in LPS-induced endotoxemia through the suppression of the TLR4/NF-κB signaling axis, positioning it as a promising therapeutic candidate for vascular inflammatory disorders. Full article
(This article belongs to the Special Issue Marine Anti-inflammatory Agents )
Show Figures

Figure 1

Back to TopTop